ABSTRACT
Prostate cancer is extremely common but causes death in only a minority of men in whom it develops, facts that raise issues regarding screening and treatment morbidity. Two large trials of screening with prostate-specific antigen (PSA) measurements came to seemingly opposite conclusions. Furthermore, a large trial of selenium and vitamin E found that these agents have no value as preventive agents.
Footnotes
↵* Dr. Klein has disclosed that he receives research support from Abbott Diagnostics and Genomic Health companies and consulting fees from Amgen and GlaxoSmithKline companies.
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.